KDOQI (Kidney Disease Outcomes Quality Initiative)


NKF KDOQI GUIDELINES

Executive Summaries | Anemia | Hemodialysis | Peritoneal Dialysis |
Vascular Access | Nutrition | CKD 2002 | Dyslipidemias | Bone Metabolism | Hypertension and Antihypertensive Agents | Cardiovascular Disease in Dialysis Patients | History of KDOQI |

KDOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients


KDOQI Disclaimer

Section I: Use of the Guidelines

These Guidelines are based upon the best information available at the time of publication. They are designed to provide information and assist decision-making. They are not intended to define a standard of care, and should not be construed as one. Neither should they be interpreted as prescribing an exclusive course of management.

Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every health-care professional making use of these Guidelines is responsible for evaluating the appropriateness of applying them in the setting of any particular clinical situation.

The recommendations for research contained within this document are general and do not imply a specific protocol.

Section II: Development of the Guidelines

The National Kidney Foundation makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the working group.

Specifically, all members of the working group are required to complete, submit, and sign a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest. All affiliations are published in their entirety at the end of this publication in the Work Group Biographies section.

In citing this document, the following format should be used: National Kidney Foundation. KDOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis 45:S1-S154, 2005 (suppl 3)

The development of the KDOQI Cardiovascular Disease in Dialysis Patients Clinical Practice Guidelines was supported by an educational grant from Satellite Healthcare, Inc.

Additional support was received from Genzyme Therapeutics.

The National Kidney Foundation gratefully acknowledges the support of Amgen Inc. as the founding and principal sponsor of KDOQI.